Tina deVries
Overview
Explore the profile of Tina deVries including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
Okuda D, Kantor D, Jaros M, deVries T, Hunter S
Brain Commun
. 2023 Mar;
5(1):fcad026.
PMID: 36861013
Baclofen, a racemic γ-aminobutyric acid B receptor agonist, is commonly used for the management of multiple sclerosis-related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active...
2.
Okuda D, Kantor D, Jaros M, deVries T, Hunter S
Brain Commun
. 2022 Dec;
4(6):fcac300.
PMID: 36519155
Baclofen, a racemic GABA-B (GABA) receptor agonist, is commonly used for the management of multiple sclerosis-related spasticity but is associated with frequent dosing and poor tolerability. Arbaclofen, the active R-enantiomer...
3.
Rascol O, Tonges L, deVries T, Jaros M, Quartel A, Jacobs D
Parkinsonism Relat Disord
. 2022 Mar;
96:65-73.
PMID: 35227940
Background: Immediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine formulation OS320 (OSMOLEX ER®) contains an IR outer layer and ER core...
4.
deVries T, Dentiste A, Handiwala L, Jacobs D
Neurol Ther
. 2019 Aug;
8(2):449-460.
PMID: 31372936
Introduction: In February 2018, OS320-an amantadine extended-release (ER) tablet formulation with once-daily morning administration-was approved for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults. The purpose of...
5.
deVries T, Dentiste A, Di Lea C, Pichette V, Jacobs D
CNS Drugs
. 2019 Jul;
33(8):783-789.
PMID: 31342404
Background: An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson's disease and drug-induced extrapyramidal reactions in adults. Objectives: To determine...
6.
Jones T, Ellman H, deVries T
J Drugs Dermatol
. 2017 Oct;
16(10):1022-1028.
PMID: 29036256
Objective: To characterize minocycline pharmacokinetics and relative bioavailability following multiple-dose topical administration of minocycline hydrochloride (HCl) foam 4% (FMX101 4%) as compared with single-dose oral administration of minocycline HCl extended-release...